Most Popular Stories
- Top biotech, biopharma employers
- State med board disciplinary action numbers fall again
- Case study: Medical group brings free annual care to rural U.S.
- ALSO NOTED: Doctors support national health insurance; Humana covers oral cancer screenings; and much more...
- MA hospitals go green
- Turmoil ensues as Wells, Citi fight for Wachovia
Poll
Featured Jobs
-
Tennessee Gastroenterologist
StaffPointe, LLC - near Memphis , TN -
Pennsylvania Family Practice
StaffPointe, LLC - Pittsburgh , PA -
Texas ICU RN (Traveler)
StaffPointe, LLC - east, TX -
New York Pediatric Neurologist
StaffPointe, LLC - west , NY -
North Carolina Ophthalmologist
StaffPointe, LLC - Raleigh , NC
Events
- Middle East Healthcare Expansion Congress 2008
Oct 13-14 — Dubai, UAE - World Health Care Congress
April 14-16, 2009 — Washington, DC - Build High Performing Healthcare Teams with Pat Lencioni
Dec. 3-4, — Dallas - Fall Health IT Summit
Oct 27-28 — Los Angeles, CA
Latest News
Popular Topics
Whitepapers
- The Challenge of Securing Hard to Patch Servers in Health Care Environments
- Engaging Physicians in a Shared Quality Agenda
- Enhancing Telecom Expense Management Through Enterprise Business Intelligence
- New Forrester Report: Data Loss Prevention Solutions
- Premerus Issues Study Addressing Medical Misdiagnosis in America 2008
- IM and Presence: Achieving Mission Critical Status in the Enterprise
Analyst says Tenet poised for major turnaround
This must be satisfying for Tenet execs to see: A major healthcare analyst has turned tail and upgraded the hospital company's rating dramatically, after slamming it less than a year ago and suggesting it would soon go out of business.
Eight months ago, leading healthcare analyst Ken Weakly of Credit Suisse Securities predicted that Tenet's stock would drop to $2 per share from its then-status of $3.67 per share, rating the stock as "under perform." At the time, Weakly noted that several threats, including the chain's reliance on Medicare outlier payments and lower-than-needed patient volumes, posed serious threats to the chain's survival, and predicted that within three years it would go bankrupt. Not only that, the company was still recovering from its protected legal troubles, which included a $725 million payment to settle Medicare billing charges.
Now, however, Weakly has done a complete turnaround, changing his rating to "outperform" and pushing his price forecast up to $8 per share from $6. With Tenet not only boosting patient volumes, but also seeing better pay from health plans, the company now has a "sustainable economic profile," Weakly wrote in a recent note to investors. In addition to taking in more money, Tenet has cut costs aggressively, eliminating almost 1,500 jobs in 2007, shed its poorer performing hospitals and re-structured services to focus on more profitable eras like neonatal care and cancer treatment.
To learn more about Tenet's situation:
- read this article from The Dallas Morning News
- read this piece from The Boston Globe
PLUS: Though Tenet may still be struggling, hospital operator Universal Health Services is going strong, with profits having jumped nearly 25 percent during the first quarter of this year.
Related Articles:
Tenet turning around: Admissions grow, losses fall
Tenet may be ready for comeback
Tenet execs detail turnaround progress
Tenet fights bankruptcy rumors
Related Stories
- HMA, Tenet still face financial struggles
- Miami Medicare fraud leaders turn selves in
- Tenet sees $31 million loss for Q1
- Tough challenges on the horizon
- Health plans need new approaches to profitability
- ALSO NOTED: FL hospitals see dramatic growth in uncompensated care; LifePoint wants to buy; and much more...
- Insurer troubles could mean more bad debt for providers
- CMS sets plans for RAC contractor expansion
- Study: Never events a major factor in hospital liability costs
- Study: 40 percent of hospitals expect to owe money to Medicare under RAC
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
- Impact of Pharmacogenomics on Public Healthcare Policy
- The Cardiovascular Disorders Market Outlook to 2012
- 2008 Trends to Watch: Pharmaceutical Technology
- Pharmaceutical Pricing and Reimbursement: Strategies for market access across the US, Europe, Japan and other key geographies
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site MapTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceSarbox | FierceHealthcare | FierceHealthFinance | FierceHealthIT | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceBiotech | FierceBioResearcher | FiercePharma | FierceVaccines | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe© 2008 FierceMarkets, Inc. All rights reserved. |
![]() |



